查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1614240

食道癌市场：按类型、癌症阶段、治疗、最终用户分类 - 全球预测 2025-2030

Esophageal Cancer Market by Type (Esophageal Adenocarcinoma, Esophageal Squamous-Cell Carcinoma), Cancer Phase (Phase I, Phases II, Phases III), Treatment, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年食道癌市场价值为149亿美元，预计2024年将达到160.8亿美元，复合年增长率为8.26%，到2030年将达到259.9亿美元。

食道癌市场包括旨在对抗这种侵袭性癌症的各种诊断、治疗和研究方法。这部分至关重要，因为食道癌是全球第六大癌症死亡原因，需要早期发现并推动有效治疗方法。应用范围从诊断影像和切片检查等早期诊断工具到手术干预、化疗、标靶治疗和新免疫疗法等高级治疗。最终用途市场包括医院、癌症治疗中心、诊断实验室等。该市场的成长主要受到人口老化、胃食道逆流（GERD）、巴瑞特氏食道症盛行率上升以及吸烟和饮酒等生活方式等危险因子盛行率上升的显着推动。微创手术的技术进步和个人化医疗的发展也是关键驱动力。随着生物标记研究的进步，用于早期检测和开发针对特定基因突变的客製化治疗方法，也存在机会。投资于细胞疗法和免疫查核点抑制剂等尖端治疗方法研发的公司将拥有竞争优势。挑战包括治疗费用高、早期诊断困难以及对常规治疗方法有抵抗力的疾病的异质性。此外，严格的监管标准和广泛的临床测试的需要可能会抑制市场的快速渗透。创新可能集中在改进液态切片技术和利用人工智慧来提高诊断准确性和计划治疗。儘管市场充满活力，大型製药公司之间的竞争也很激烈，但生技新兴企业也有机会利用颠覆性技术实现大跃进。强调合作研究伙伴关係和策略联盟可能有利于提高研究能力和有效地将新治疗方法商业化。

主要市场统计
基准年[2023] 149亿美元
预计年份 [2024] 160.8亿美元
预测年份 [2030] 259.9亿美元
复合年增长率（%） 8.26%

市场动态：揭示快速发展的食道癌市场的关键市场洞察

食道癌市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 食道癌盛行率不断上升，需要及时治疗
    • 先进食管癌诊断技术的开发
    • 政府对癌症研究的倡议和资助
  • 市场限制因素
    • 食道癌治疗的召回问题
  • 市场机会
    • 食道癌治疗取得进展并获得政府核准
    • 标靶治疗和免疫治疗的出现
  • 市场问题
    • 治疗开发的复杂性

波特五力：驾驭食道癌市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解外部对食道癌市场的影响

外部宏观环境因素对食道癌市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解食道癌市场的竞争格局

对食道癌市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵：食道癌市场供应商绩效评估

FPNV定位矩阵是评估食道癌市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製食道癌市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，食道癌市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 食道癌盛行率不断上升，需要及时治疗
      • 先进食管癌诊断技术的开发
      • 政府对癌症研究的倡议和资助
    • 抑制因素
      • 食道癌药物不利事件回忆
    • 机会
      • 获得政府核准的食道癌药物进展
      • 标靶治疗和免疫治疗的出现
    • 任务
      • 治疗开发的复杂性
  • 市场区隔分析
    • 类型：因吸烟、饮酒等不良习惯导致食道鳞状细胞癌高发
    • 治疗：手术前合併化疗及放射线治疗
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章食道癌市场：依类型

  • 介绍
  • 食道腺癌
  • 食道鳞状细胞癌

第七章 食道癌市场：依癌症分期

  • 介绍
  • 第一阶段
  • 第二阶段
  • 第三阶段

第八章食道癌市场：依治疗分类

  • 介绍
  • 化疗
  • 放射治疗
  • 外科手术

第 9 章 食道癌市场：依最终使用者分类

  • 介绍
  • 癌症研究所
  • 诊断实验室
  • 医院/诊所

第10章美洲食道癌市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太食道癌市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲食道癌市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 舒格利单抗合併化疗核准中国核准用于治疗食道鳞状细胞癌
    • 中国生物技术公司核准治疗食道癌
    • 信达生物公布ORIENT-15的最终分析结果，这是一项3期研究，研究信迪利单抗和化疗联合治疗作为食道鳞状细胞癌的一线治疗
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd
  • Johnson & Johnson Private Limited
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-757B1C9CB069

The Esophageal Cancer Market was valued at USD 14.90 billion in 2023, expected to reach USD 16.08 billion in 2024, and is projected to grow at a CAGR of 8.26%, to USD 25.99 billion by 2030.

The esophageal cancer market encompasses a range of diagnostic, treatment, and research processes aimed at addressing this aggressive form of cancer. This sector is crucial as esophageal cancer is the sixth leading cause of cancer death globally, necessitating advancements in early detection and effective therapies. Its applications span from early-stage diagnostic tools, including imaging and biopsy, to advanced treatments like surgical interventions, chemotherapy, targeted therapy, and emerging immunotherapies. End-use markets include hospitals, cancer treatment centers, and diagnostic laboratories. Growth in this market is significantly influenced by an increasing prevalence of risk factors such as aging populations, rising incidence of gastroesophageal reflux disease (GERD), Barrett's esophagus, and lifestyle elements including smoking and alcohol use. Technological advancements in minimally invasive surgical procedures and the development of personalized medicine are also key growth drivers. Opportunities exist in advancing biomarker research for early detection and targeting specific genetic mutations to develop tailored treatments. Companies that invest in advanced R&D for cutting-edge treatments, including cell-based therapies and immune checkpoint inhibitors, stand to gain a competitive edge. Challenges include high treatment costs, difficulties in early diagnosis, and the heterogeneous nature of the disease making it resistant to conventional therapies. Additionally, stringent regulatory norms and requirement for extensive clinical trials can impede quick market penetration. Innovation could focus on improving liquid biopsy technologies and the use of artificial intelligence for better diagnostic accuracy and treatment planning. The market is dynamic, with strong competition among pharmaceutical giants, but also offers opportunities for biotech startups to make significant strides with disruptive technologies. Emphasizing collaborative research partnerships and strategic alliances would be beneficial to enhance research capabilities and commercialize new therapies effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 14.90 billion
Estimated Year [2024] USD 16.08 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 8.26%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Esophageal Cancer Market

The Esophageal Cancer Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of esophageal cancer and need for timely treatment
    • Development of sophisticated esophageal cancer diagnostic techniques
    • Government initiatives and funding for cancer research
  • Market Restraints
    • Adverse recalls of esophageal cancer drugs
  • Market Opportunities
    • Advancements in esophageal cancer medications with favorable government approvals
    • Emergence of targeted therapies and immunotherapies
  • Market Challenges
    • Complexity in development of therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Esophageal Cancer Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Esophageal Cancer Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Esophageal Cancer Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Esophageal Cancer Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Esophageal Cancer Market

A detailed market share analysis in the Esophageal Cancer Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Esophageal Cancer Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Esophageal Cancer Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Esophageal Cancer Market

A strategic analysis of the Esophageal Cancer Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Esophageal Cancer Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Aurobindo Pharma Limited, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co., Ltd, Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc, Sanofi S.A., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Esophageal Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Esophageal Adenocarcinoma and Esophageal Squamous-Cell Carcinoma.
  • Based on Cancer Phase, market is studied across Phase I, Phases II, and Phases III.
  • Based on Treatment, market is studied across Chemotherapy, Radiotherapy, and Surgery.
  • Based on End-Users, market is studied across Cancer Research Institutes, Diagnostic Laboratories, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of esophageal cancer and need for timely treatment
      • 5.1.1.2. Development of sophisticated esophageal cancer diagnostic techniques
      • 5.1.1.3. Government initiatives and funding for cancer research
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of esophageal cancer drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in esophageal cancer medications with favorable government approvals
      • 5.1.3.2. Emergence of targeted therapies and immunotherapies
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in development of therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: High prevalence of esophageal squamous-cell carcinoma owing to smoking, alcohol consumption, other toxic habits
    • 5.2.2. Treatment: Adoption of chemotherapy and radiotherapy in combination before surgery
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Esophageal Cancer Market, by Type

  • 6.1. Introduction
  • 6.2. Esophageal Adenocarcinoma
  • 6.3. Esophageal Squamous-Cell Carcinoma

7. Esophageal Cancer Market, by Cancer Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phases II
  • 7.4. Phases III

8. Esophageal Cancer Market, by Treatment

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Radiotherapy
  • 8.4. Surgery

9. Esophageal Cancer Market, by End-Users

  • 9.1. Introduction
  • 9.2. Cancer Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Clinics

10. Americas Esophageal Cancer Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Esophageal Cancer Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Esophageal Cancer Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sugemalimab Plus Chemo Receives Approval in China for Esophageal Squamous Cell Carcinoma
    • 13.3.2. China-based biotech receives approval for esophageal cancer treatment
    • 13.3.3. Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca plc
  • 6. Aurobindo Pharma Limited
  • 7. Bausch Health Companies Inc.
  • 8. Bayer AG
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Cipla Inc.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd
  • 14. GlaxoSmithKline Plc
  • 15. Hikma Pharmaceuticals PLC
  • 16. Jiangsu Hengrui Medicine Co., Ltd
  • 17. Johnson & Johnson Private Limited
  • 18. LEO Pharma A/S
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Otsuka Pharmaceutical Co., Ltd.
  • 22. Pfizer Inc
  • 23. Sanofi S.A.
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ESOPHAGEAL CANCER MARKET RESEARCH PROCESS
  • FIGURE 2. ESOPHAGEAL CANCER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ESOPHAGEAL CANCER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ESOPHAGEAL CANCER MARKET DYNAMICS
  • TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL ADENOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PHASES III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY CANCER PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ESOPHAGEAL CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 190. ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2023